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Acute-phase markers, such as C-reactive protein (CRP), interleukin-6 (IL-6) and tumor
necrosis factor alpha (TNF-a), have been studied in inflammatory and malignant disorders.
We examined the diagnostic value of these markers for the differentiation among
parapneumonic, tuberculous and malignant effusions.
We studied 124 patients with pleural effusions, classified as exudates [total (n ¼ 97),
parapneumonic (n ¼ 15), tuberculous (n ¼ 25), malignant (n ¼ 57)] and transudates due to
congestive heart failure (n ¼ 27). CRP, IL-6 and TNF-a were measured in pleural fluid and
serum.
Pleural fluid CRP was higher in parapneumonic compared to tuberculous and malignant
effusions, providing 100% sensitivity for a cut-off point of 5.3mg/dL. IL-6 was higher in
both parapneumonic and tuberculous compared to malignant effusions. TNF-a was higher
in tuberculous compared to malignant effusions, providing 96.0% sensitivity, and 93.0%
specificity for a cut-off point of 88.1 pg/mL. Pleural fluid CRP levels were lower than serum
in all groups, probably reflecting systemic inflammation, whereas IL-6 and TNF-a were
higher in pleural fluid indicating local production.
Our data suggest that these markers may provide useful information for the differentiation
of infectious and malignant effusions in clinical practice. However, further studies are
needed for the validation of these findings in usual clinical circumstances.
& 2006 Published by Elsevier Ltd.Published by Elsevier Ltd.
tk@otenet.gr (T.S. Kiropoulos).
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Acute phase markers in pleural effusions 911Introduction
The diagnosis and management of pleural effusions remains
a clinical challenge bearing a significant cost both to the
patients and the health care system.1 In everyday clinical
practice a variety of laboratory tests are in use for the
differential diagnosis of pleural effusions; nevertheless, a
significant proportion remain undiagnosed.1 A major pro-
blem remains the differentiation between malignant and
infectious effusions, due to their different outcome and
management; thus, the need for markers that may help in
this differentiation is imperative. Acute-phase proteins,
such as C-reactive protein (CRP), have been implicated in
various infectious inflammatory and advanced malignant
states, and these proteins are regulated by proinflammatory
cytokines, such as interleukin-6 (IL-6) and tumor necrosis
factor alpha (TNF-a).2
C-reactive protein is currently widely used as a marker of
inflammation and tissue injury.2 CRP is synthesized in the
liver in response to various stimuli3 and it is production is
enhanced by IL-6 and TNF-a.4 Increased serum CRP levels
have been found in a number of pulmonary disorders,
including bacterial infections, malignancies, and pulmonary
thromboembolism.5,6 However, only a few studies have
focused on the role of CRP in pleural effusions.7–9 IL-6 is the
chief stimulator of the production of most acute-phase
proteins and other cytokines, and regulates the synthesis of
TNF-a and CRP.10 TNF-a is another proinflammatory cytokine
with a cardinal role in various inflammatory responses.11,12
TNF-a is released by mesothelial cells in pleura and interacts
with them leading to cytokine production,13 especially in
infectious pleural effusions.14 Pleural fluid IL-6 and TNF-a
levels have not been thoroughly studied and the results up
to date are contradictory.15–18
The primary aim of this study was to assess the levels of
three major acute phase response markers, i.e. CRP, IL-6
and TNF-a, in the pleural fluid and serum of patients with
strictly characterized pleural effusions, in order to evaluate
their usefulness in the differentiation among parapneumo-
nic, tuberculous and malignant effusions. Additionally, we
investigated the performance of these biomarkers for the
differentiation between exudates and transudates.
Materials and methods
Study subjects
We studied prospectively 170 consecutive patients admitted
with pleural effusions between September 2003 and
February 2005. Forty six of the 170 patients that were
initially evaluated were excluded from this study for the
following reasons: diagnosis other than congestive heart
failure, parapneumonic, tuberculous or malignant etiology
was established; inability to establish a definite diagnosis; or
presence of more than one plausible causes of pleural
effusions. Empyemas and complicated parapneumonic effu-
sions were additionally excluded from our study as in those
cases the final diagnosis is easy to achieve and the natural
history of these effusions is completely different from that
of uncomplicated parapneumonic, tuberculous or malignant
effusions. The study protocol was approved by the localethics committee and all subjects provided written in-
formed consent.Study design
Pleural fluid samples were obtained with the first successful
thoracentesis before treatment, immediately after admis-
sion. Simultaneously, 10mL of venous blood were obtained.
Samples were analyzed for total and differential cell count,
glucose, total protein and LDH. Additionally, cytologic
examinations and cultures for common pathogens and
Mycobacterium tuberculosis were routinely performed in
all pleural fluid samples. Aliquots of pleural fluid and blood
samples were immediately centrifuged at 1500g for 15min
at 4 1C and the supernatants were stored at 80 oC for CRP,
IL-6 and TNF-a measurements.Methods
The determination of the etiology of pleural effusions was
based on widely accepted criteria, as previously de-
scribed.19 Briefly, parapneumonic effusions were character-
ized by coexistence of pneumonia, response to antibiotics
and/or pleural fluid neutrophilia (empyemas and compli-
cated parapneumonic effusions that needed chest drainage
were excluded); malignant effusions were diagnosed by
cytologic or histologic examination; tuberculous (TB) effu-
sions were diagnosed with the presence of positive stain or
culture for Mycobacterium tuberculosis in the pleural fluid,
sputum or pleural biopsy; or in the presence of typical
caseating granulomas in pleural biopsy. In two of the
patients without positive cultures or histopathological
evidence, the diagnosis of tuberculous pleurisy was based
on the following criteria: (i) adenosine deaminase levels in
pleural fluid greater than 40 U/L;20 (ii) exclusion of any
other cause of pleural effusion; and (iii) response to
antituberculous therapy. All transudative effusions were
transudates in patients diagnosed with congestive heart
failure (CHF). The differentiation between exudates and
transudates was made by two experienced physicians (K.K.
and K.I.G.) blinded to the results of the CRP, IL-6 and TNF-a
measurements at the time of the diagnosis. The classifica-
tion was based on Light’s criteria, using serum and pleural
fluid total protein and LDH measurements,21 and was further
confirmed by the final diagnosis. Specifically, parapneumo-
nic, tuberculous and malignant effusions were exudates,
whereas effusions due to CHF were transudates.CRP, IL-6 and TNF-a measurements
Pleural fluid and serum CRP measurements were performed
by immunonephelometry with the Behring Nephelometer
Analyzer II (BNII), using the N High Sensitivity kit (Dade
Behring Gmbh, Germany). The appropriate control and
standard sera were provided by the same company,
according to the manufacturer’s instructions. IL-6 and
TNF-a levels were measured with a commercially available
enzyme-immunosorbent assay kit (Biosource Europe S.A.)
according to the manufacturer’s protocol. The lower limits
of detection for IL-6 and TNF-a were 2 and 3 pg/mL,
respectively.
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T.S. Kiropoulos et al.912Reproducibility of CRP, IL-6 and TNF-a measurements
The reproducibility of CRP, IL-6 and TNF-a measurements
was assessed in two consecutive measurements on the same
day in pleural fluid samples from a subgroup of 15 patients,
including 4 patients with transudative, 3 patients with
parapneumonic, 4 patients with tuberculous, and 4 patients
with malignant effusions.
Statistical analysis
Data are presented as mean7standard deviation (SD) for
data with normal distribution, and as median with inter-
quartile ranges in parenthesis for skewed data. Normality of
distribution was checked with Shapiro–Wilk’s test. Compar-
isons between two different groups were performed using
Mann–Whitney U-tests. Comparisons among more than two
groups were performed using the non-parametric Kruskal–
Wallis test. For the evaluation of the reproducibility of CRP,
IL-6 and TNF-a in pleural effusions the method described
by Bland and Altman22 was used. P-values o0.05 were
considered statistically significant.
For the evaluation of the diagnostic performance of CRP,
IL-6 and TNF-a levels as markers for the differential
diagnosis between pleural effusions of different origin,
receiver operator characteristics (ROC) analysis was per-
formed for all significant differences between groups. ROC
curves were generated by plotting the sensitivity against
1-specificity, and the area under the curve (AUC) with 95%
confidence intervals (95% CI) was calculated. The optimum
cut-off point from the ROC analysis was established by
selecting the value that provides the greatest sum of
sensitivity and specificity, i.e. the point closest to the upper
left point of the ROC plot. For the optimum cut-off point
provided by each ROC analysis, sensitivity, specificity,
positive likelihood ratio (+LR), negative likelihood ratioTable 1 Demographic data and pleural fluid characteristics of
Transudates
(n ¼ 27)
Age (years) 7079
Gender (male/female) 21/6
Pleural fluid cells 8587405
Pleural fluid lymphocytes (%) 50.4721.4
Pleural fluid neutrophils (%) 13.279.0
Pleural fluid glucose (mg/dL) 126.3732.5
Total protein pleural fluid (g/L) 2.170.7
Total protein serum (g/L) 6.071.1
Total protein pleural fluid/serum ratio 0.3470.1
Pleural fluid LDH (U/L) 112734
Serum LDH (U/L) 218770
LDH pleural fluid/serum ratio 0.5070.10
Data are presented as mean7SD for normally distributed data or medi
pleural fluid to serum ratio.
yMalignant effusions include effusions due to lung cancer (n ¼ 28) an
breast (n ¼ 7), ovary (n ¼ 6), renal cell carcinoma (n ¼ 1), urinary
congestive heart failure.
*Statistically significant difference (Po0.05) between exudates (para
#Statistically significant difference (Po0.05) between parapneumon
zStatistically significant difference (Po0.05) between tuberculous o(LR), positive predictive value (PPV), and negative
predictive value (NPV) were calculated using standard
formulas. Once these terms would be complementary for
each pair of disorders, we refer to them regarding the first
of the two disorders mentioned. For the calculation of the
ROC curves and AUCs we have used the MedCalc version 6.15
software (MedCalc, Mariakerke, Belgium) and for the rest of
the analyses the GraphPad Prism version 4.00 software
(GraphPad Software, CA, USA).
Results
General characteristics of pleural effusions
The demographic data and the pleural fluid characteristics
of the 124 patients that were included in the study are
presented in Table 1. The levels of CRP, IL-6 and TNF-a in
pleural fluid and serum of the study subjects are presented
in Table 2 and in Fig. 1(A-C).
Pleural fluid levels of CRP, IL-6 and TNF-a in
exudates
CRP measurements
Pleural fluid CRP levels were significantly higher in patients
with parapneumonic compared to tuberculous (Po0.0001)
or malignant (P ¼ 0.001) effusions. Additionally, pleural
fluid CRP was higher in tuberculous compared to malignant
effusions (P ¼ 0.02) (Table 2, Fig. 1A). No significant
differences were observed in CRP measurements between
malignant effusions due to lung cancer and other malignant
effusions.
The diagnostic performance from the ROC analysis of
pleural fluid CRP values is presented in Table 3. Pleural fluidthe study population (n ¼ 124).
Parapneumonic Tuberculous Malignanty
(n ¼ 15) (n ¼ 25) (n ¼ 57)
50722 55716.5 70711
11/4 17/8 39/18
1001076006* 276771301* 199771419*
12.876.7# 77.1713.0z 60.8718.0z
73.8718.6# 11.576.7 17.3711.9
49.2748.1# 90.7722.1 111.8741.8
5.070.6* 5.270.7* 4.570.9*
7.170.7 7.070.8 6.471.0
0.7170.1* 0.7470.1* 0.7070.1*
256372400* 5557274* 316 (224, 469)*
203755 226769 3097173
14.60718.80* 2.6071.50* 1.39 (0.87, 1.80)*
an (interquartile ranges) for skewed data. PF: pleural fluid; PF/S:
d other malignant effusions (n ¼ 29). Other malignancies include
(n ¼ 4) and unknown origin (n ¼ 11). All transudates are due to
pneumonic, tuberculous or malignant effusions) vs. transudates.
ic vs. all other types of effusions.
r malignant effusions vs. parapneumonic or transudates.
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Table 2 Levels of CRP, IL-6 and TNF-a in the pleural fluid and serum of patients with transudative or exudative pleural
effusions.
Transudates Exudates Parapneumonic Tuberculous Malignant
(n ¼ 27) (n ¼ 97) (n ¼ 15) (n ¼ 25) (n ¼ 57)
CRP (mg/dL)
PF 0.8470.76 2.9 (1.40, 7.35) * 12.2575.32 *,#,y 4.2472.40 * y 1.9 (0.85, 3.60) *
Serum 2.2271.61 7.2 (3.0, 15.8) * 24.1779.30 *,#,y 9.0475.58 * y 3.7 (2.05, 11.70) *
PF/S 0.5070.63 0.44 (0.28, 0.60) 0.5370.23 0.5370.24 0.41 (0.22, 0.60)
IL-6 (pg/mL)
PF 8147594 14526710881 * 2276278124 *,y 2426878640 *,y 808577191 *
Serum 43.8742.6 90.2 (49.6, 173.3) * 150.37125.6 *,y 133.8799.3 *,y 72.1 (32.5, 181.5) *
PF/S 19.0 (12.1, 29.0) 114.3 (62.5, 203.6) * 225.97167.8 *,y 240.87129.9 *,y 76.5 (40.2, 141.5) *
TNF-a (pg/mL)
PF 18.8711.8 53.9 (33.3, 129.0) * 90.2752.8 *,#,y 215.37124.2 *,y 45.4732.7 *
Serum 20.7714.2 24.9 (18.1, 36.4) * 28.3715.2 *,# 37.3719.2 *,y 25.1712.1 *
PF/S 1.0470.6 2.2 (1.46, 4.56) * 3.673.1 *,#,y 6.673.8 *,y 1.5 (1.2, 2.4) *
Data are presented as mean7SD for normally distributed data or median (interquartile ranges) for skewed data. PF: pleural fluid; PF/S:
pleural fluid to serum ratio.
*: Statistically significant difference (Po0.05) between exudates (parapneumonic, tuberculous or malignant effusions) and
transudates.
#: Statistically significant difference (Po0.05) between parapneumonic and tuberculous effusions.
y: Statistically significant difference between parapneumonic and malignant effusions.
y: Statistically significant difference (Po0.05) between tuberculous and malignant effusions.
Acute phase markers in pleural effusions 913CRP proved a good marker for the differentiation of
parapneumonic effusions from tuberculous and/or malig-
nant effusions. Using a cut-off point of 5.3mg/dL, CRP
presented 100% sensitivity and 79.0% specificity for the
diagnosis of parapneumonic vs. combined tuberculous and
malignant effusions (Fig. 2A). Comparable findings were
observed for the differentiation between parapneumonic
and malignant effusions using a cut-off point of 5.0mg/dL,
whereas CRP values48.7mg/dL presented 80.0% sensitivity
but 100% specificity for the differentiation between para-
pneumonic and tuberculous effusions.IL-6 measurements
Pleural fluid IL-6 levels were similar in tuberculous and
parapneumonic effusions (P ¼ ns) and significantly higher in
those two groups compared to malignant effusions
(Po0.0001 for both comparisons). (Table 2, Fig. 1B) No
significant differences were observed in IL-6 measurements
between malignant effusions due to lung cancer and other
malignant effusions.
The diagnostic performance from the ROC analysis of
pleural fluid IL-6 values is presented in Table 4. Pleural
fluid IL-6 proved a good marker for the differentiation
of parapneumonic and/or tuberculous effusions from
malignant effusions. Using a cut-off point of 13750 pg/mL,
IL-6 presented 96.0% sensitivity and 80.7% specificity for
the differentiation between tuberculous and malignant
effusions. Additionally, using a cut-off point of 12680 pg/
mL, IL-6 presented 94.9% sensitivity and 75.9% specificity
for the differentiation of infectious (parapneumonic and
tuberculous) vs. malignant effusions (Fig. 2B); similar
findings were observed with the same cut-off point regard-
ing the differentiation of parapneumonic and malignant
effusions.TNF-a measurements
Pleural fluid TNF-a levels were significantly higher in
patients with tuberculous compared to malignant
(Po0.0001) and parapneumonic (P ¼ 0.0007) effusions.
Additionally, TNF-a levels were higher in parapneumonic
compared to malignant effusions (P ¼ 0.0001) (Table 2, Fig.
1C). No significant differences were observed in TNF-a
measurements between malignant effusions due to lung
cancer and other malignant effusions.
The diagnostic performance from the ROC analysis of
pleural fluid TNF-a values is presented in Table 5. Pleural
fluid TNF-a proved a good marker for the differentiation of
tuberculous from malignant and parapneumonic effusions.
Using a cut-off point of 88.1 pg/mL, TNF-a presented 96.0%
sensitivity and 93.0% specificity for the differentiation
between tuberculous and malignant effusions (Fig. 2C).
Similar performance was observed for the differentiation of
tuberculous vs. combined parapneumonic and malignant
effusions.Pleural fluid and serum levels of CRP, IL-6, and
TNF-a
Pleural fluid CRP levels were lower than serum levels in
all exudates (P ¼ 0.0002 for parapneumonic, P ¼ 0.0003
for tuberculous, and Po0.0001 for malignant effusions,
Table 2). Interestingly, the ratio of pleural fluid to serum
CRP did not differ among the different groups (P ¼ ns),
presenting mean values that approximate 0.5 in all types
of effusions. In contrast, pleural fluid levels of IL-6 and
TNF-a were higher than serum levels (IL-6: Po0.0001 for all
types of effusions; TNF-a: P ¼ 0.0001 for parapneumonic,
and Po0.0001 for tuberculous and malignant effusions;
Table 2).
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Table 3 Diagnostic performance of pleural fluid CRP for the differential diagnosis of infectious and malignant effusions at
the optimal cut-off points of the ROC analysis curves.
Optimal cut-off
point (mg/dL)
Sensitivity
(%)
Specificity
(%)
+LR LR PPV (%) NPV (%) AUC (95% CI)
PE vs. TB 48.7 80.0 100.0 420.00 0.20 100.0 89.3 0.955 (0.837–0.994)
PE vs. MAL 45.0 100.0 82.5 5.70 0.00 60.0 100.0 0.965 (0.892–0.993)
TB vs. MAL 41.4 100.0 45.6 1.84 0.00 44.6 100.0 0.719 (0.609–0.813)
PE vs. TB and MAL 45.3 100.0 79.0 4.76 0.00 46.9 100.0 0.961 (0.901–0.990)
TB vs. PE and MAL 41.4 100.0 36.1 1.57 0.00 35.2 100.0 0.579 (0.474–0.678)
PE and TB vs. MAL 41.7 97.5 41.9 1.92 0.05 57.4 96.6 0.811 (0.719–0.884)
PE, parapneumonic effusions; TB, tuberculosis; MAL, malignancy; +LR, positive likelihood Ratio; LR, negative likelihood ratio; PPV,
positive predictive value; NPV, negative predictive value; AUC, area under the curve; CI: confidence intervals.
Figure 1 Acute phase markers in the pleural fluid of patients with parapneumonic (n ¼ 15 m), tuberculous (n ¼ 25 ~), and
malignant (n ¼ 57K) effusions. Each symbol represents one individual and horizontal bars represent mean values. (A) Pleural fluid
CRP levels. The dotted line represents the optimal cut-off point for the differentiation between parapneumonic vs. combined
tuberculous and malignant effusions. (B) Pleural fluid IL-6 levels. The dotted line represents the optimal cut-off point for the
differentiation between infectious (parapneumonic and tuberculous) vs. malignant effusions. (C) Pleural fluid TNF-a levels. The
dotted line represents the optimal cut-off point for the differentiation between tuberculous vs. malignant effusions.
T.S. Kiropoulos et al.914Differentiation between exudates and transudates
Pleural fluid CRP, IL-6 and TNF-a levels were significantly
higher in patients with exudates compared to transudates
(Table 2). However, in the ROC analyses, only IL-6 presented
acceptable performance as a marker for the differentiationbetween exudates and transudates, presenting 95.8%
sensitivity, 92.6% specificity and AUC 0.983 (95% CI
0.942–0.997) in the ROC analysis for a cut-off point of
1375 pg/mL. Pleural fluid CRP and TNF-a were poor
predictors for the differentiation between exudates and
transudates (data not presented).
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Figure 2 Receiver operator characteristic (ROC) analysis curves of acute phase markers in pleural fluid for the differentiation of
infectious and malignant effusions. (A) ROC curve of CRP for the differentiation of parapneumonic vs. tuberculous and malignant
effusions (optimal cut-off pointK, 5.3mg/dL). (B) ROC curve of IL-6 for the differentiation of parapneumonic and tuberculous vs.
malignant effusions (optimal cut-off point K, 12,680 pg/mL). (C) ROC curve of TNF-a for the differentiation of tuberculous vs.
malignant effusions (optimal cut-off point K, 88.1 pg/mL).
Acute phase markers in pleural effusions 915Reproducibility of acute phase markers in pleural
fluid
The measurements of acute phase markers in pleural fluid
samples were highly reproducible. CRP levels on two
consecutive measurements were 5.9275.17mg/dL and
5.8375.01mg/dL, respectively. The mean difference with
limits of agreement was 0.0970.90 (mean72SD) and all
values were within the limits of agreement in the Bland and
Altman plot.IL-6 levels on two consecutive measurements were
12.502710.873 and 12.339710.831 pg/mL, respectively.
The mean difference with limits of agreement was
1637642 (mean72SD) and all values were within the limits
of agreement in the Bland and Altman plot.
TNF-a levels on two consecutive measurements were
84.9799.8 and 84.7799.4 pg/mL, respectively. The mean
difference with limits of agreement was 0.2573.87
(mean72SD) and all values were within the limits of
agreement in the Bland and Altman plot.
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Table 4 Diagnostic performance of pleural fluid IL-6 for the differential diagnosis of infectious and malignant effusions at
the optimal cut-off points of the ROC analysis curves.
Optimal cut-off
point (pg/mL)
Sensitivity
(%)
Specificity
(%)
+LR LR PPV (%) NPV (%) AUC (95% CI)
PE vs. TB 412949 20.0 96.0 5.00 0.83 75.0 66.7 0.531 (0.367–0.690)
PE vs. MAL 412680 93.3 77.2 4.09 0.09 51.9 97.8 0.910 (0.819–0.964)
TB vs. MAL 413750 96.0 80.7 4.97 0.05 68.6 97.9 0.930 (0.851–0.974)
PE vs. TB and MAL 49313 100.0 48.8 1.95 0.00 26.3 100.0 0.776 (0.680–0.854)
TB vs. PE and MAL 417215 87.5 76.7 3.76 0.16 55.3 94.9 0.852 (0.766–0.916)
PE and TB vs. MAL 412680 94.9 75.9 3.93 0.07 72.5 95.7 0.919 (0.845–0.964)
PE, parapneumonic effusions; TB, tuberculosis; MAL, malignancy; +LR, positive likelihood ratio; LR, negative likelihood ratio; PPV,
positive predictive value; NPV, negative predictive value; AUC, area under the curve; CI: confidence intervals.
Table 5 Diagnostic performance of pleural fluid TNF-a for the differential diagnosis of infectious and malignant effusions at
the optimal cut-off points of the ROC analysis curves.
Optimal cut-off
point (pg/mL)
Sensitivity
(%)
Specificity
(%)
+LR LR PPV (%) NPV (%) AUC (95% CI)
PE vs. TB 489.8 66.7 92.0 8.33 0.36 83.3 82.1 0.856 (0.7090.946)
PE vs. MAL 443.9 68.7 62.5 1.83 0.50 34.4 87.5 0.701 (0.5810.803)
TB vs. MAL 488.1 96.0 93.0 13.68 0.04 85.7 98.1 0.954 (0.8830.987)
PE vs. TB and MAL 427.1 100.0 22.0 1.28 0.00 19.0 100.0 0.556 (0.4520.657)
TB vs. PE and MAL 488.1 92.3 85.9 6.55 0.09 70.6 96.8 0.920 (0.8470.965)
PE and TB vs. MAL 488.1 75.0 93.0 10.69 0.27 88.2 84.1 0.872 (0.7890.931)
PE, Parapneumonic effusions; TB, tuberculosis; MAL, malignancy; +LR, positive likelihood ratio; LR, negative likelihood ratio; PPV,
positive predictive value; NPV, Negative Predictive value; AUC, area under the curve; CI: confidence intervals.
T.S. Kiropoulos et al.916Discussion
In this prospective study we have validated the diagnostic
performance of three acute phase response markers, i.e.
CRP, IL-6 and TNF-a, in the serum and pleural fluid of a well-
characterized population of patients with infectious and
malignant pleural effusions. The main observation of this
study is that these acute phase response markers may be
helpful for the differentiation between infectious and
malignant pleural effusions. Specifically, pleural fluid CRP
is increased in parapneumonic effusions compared to
tuberculous and malignant effusions, pleural fluid IL-6 is
increased in both tuberculous and parapneumonic effusions
compared to malignancy, and pleural fluid TNF-a may
represent a good marker for the differentiation between
tuberculous and malignant effusions. Additionally, pleural
fluid IL-6 presented acceptable performance for the
differentiation between exudates and transudates, compar-
able with that of Light’s criteria.21 Finally, the acute phase
markers measurements were highly reproducible in the
pleural fluid.
The findings of the present study may further support a
pathophysiological mechanism of the acute phase response
during the formation of infectious and malignant effusions.
Pleural fluid CPR levels are likely to reflect serum levels, as
they were significantly lower compared to serum levels in all
study groups; in contrast, IL-6 and TNF-a were higher in
pleural fluid than serum in all groups of exudates. These
findings may suggest that a local inflammatory process leadsto production of IL-6 and TNF-a in the pleural cavity, and the
consequent systemic inflammatory response is expressed by
the serum and pleural fluid levels of CRP. Based on these
findings we may hypothesize that the major proportion of
CRP is not produced in the pleural cavity and its presence in
pleural fluid may be the result of diffusion from the blood.
This is supported by previous reports suggesting that CRP is
produced mainly in the liver and may arrive in the pleural
space from plasma.2,7 This theory is further supported by
the fact that the ratio of pleural fluid to serum CRP did not
differ among study groups, being around 0.5 in mean values.
This observation is in agreement with the findings of a
previous paper by Castano-Vidriales and Amores Antequera 7
with the exception of a lower mean value of pleural fluid to
serum CRP ratio in transudates reported by these authors
(0.26 vs. 0.50 in our study). The results of both studies,
especially in exudative effusions, suggest that pleural fluid
CRP is likely to reflect systemic inflammation that may have
been induced by the local production of IL-6 and TNF-a in
the pleural cavity. An additional implication of our findings is
that serum CRP levels may be of comparable value to pleural
fluid levels for the differentiation between parapneumonic
vs. tuberculous and/or malignant effusions, and this is in
accordance with our findings (data not shown in detail).
An additional finding of our study is that pleural fluid CRP
levels were higher in parapneumonic compared to tubercu-
lous and malignant effusions. This may be attributed to
the fact that CRP plays an important role in inflammation,
as it increases profoundly in the region of inflammation.23
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Acute phase markers in pleural effusions 917The more intense inflammation of parapneumonic compared
to tuberculous or malignant effusions may account for this
difference. This finding may provide an additional marker
for the diagnosis of parapneumonic effusions, as high levels
of pleural fluid CRP present excellent sensitivity and NPV,
with acceptable specificity. Additionally, CRP was higher in
tuberculous compared to malignant effusions and this
finding is consistent with other reports.9,24,25 This has been
attributed either to local production of CRP in the pleural
space that is induced by IL-6,24,26 or to leakage of plasma
CRP via the inflamed pleura.23 Our data support the second
mechanism, as CRP levels were constantly higher in serum
compared to pleural fluid and no correlation was found
between pleural fluid IL-6 and CRP (data not shown).
Elevated IL-6 levels have been found in various inflam-
matory, infectious and malignant disorders.18 In this study
pleural fluid IL-6 levels were significantly higher in infectious
(i.e. tuberculous and parapneumonic) compared to malig-
nant effusions. A previous study reported high IL-6 levels in
tuberculous and low IL-6 levels in malignant effusions.15 The
same study reported lower levels of IL-6 in parapneumonic
compared to tuberculous effusions,15 and this finding is
consistent with the results of a recent study by Lin et al.27
and in disagreement with our findings. However, the study
by Lin et al. included complicated parapneumonic effusions
and empyemas that presented lower IL-6 levels, probably
accounting for the lower IL-6 levels in the whole para-
pneumonic group.27 Empyemas and complicated parapneu-
monic effusions were carefully excluded from our study due
to their different natural history and their obvious differ-
entiation from tuberculous and malignant effusions, and this
may account for the observed higher IL-6 levels in our
parapneumonic effusions.
In ROC analysis IL-6 provided good sensitivity and NPV for
the differentiation of tuberculous vs. malignant effusions
(cut-off level 13,750 pg/mL) and for the differentiation of
infectious (i.e. combined parapneumonic and tuberculous)
vs. malignant effusions (cut-off level 12,680 pg/mL). In-
deed, only in 1 of 25 patients in the tuberculous group IL-6
was lower than 13,750 pg/mL, whereas only in 2 of 40
patients with infectious diseases IL-6 was lower than
12,680 pg/mL. Thus, increased IL-6 is indicative of the
presence of infectious effusions; however the low specificity
of the method suggests that it is not an optimal marker to be
used alone in clinical practice.
Pleural fluid TNF-a levels were higher in tuberculous
compared to parapneumonic and malignant effusions. The
higher TNF-a levels in tuberculous effusions may be part of a
complex immune response in the pleural space, as TNF-a has
both protective and deleterious role in tuberculosis.28
Mycobacterial products are potent stimuli for TNF-a produc-
tion by monocytes,29 providing a plausible explanation for
the high levels of TNF-a in tuberculous effusions. Our results
are in accordance with other studies,30,31 but they are in
discrepancy with data reported by Xirouchaki et al.15 and
Gursel et al.32 However, these studies used different
methodology and smaller study populations. In the present
study we included a strictly characterized population and
utilized ROC analysis to demonstrate that pleural fluid TNF-a
may be a good marker for the discrimination between
tuberculous and malignant effusions. At an optimal cut-off
level of 488.1 pg/mL, which has not previously beenevaluated in the diagnostic assessment of pleural effusions,
none of the 25 tuberculous effusions was falsely character-
ized as malignant and only 3 of 57 malignant effusions were
misclassified as tuberculous, providing great sensitivity,
specificity, NPV and PPV. The gold standard for the diagnosis
of malignant effusions still remains the cytologic and/or
histologic confirmation; nevertheless, when available, TNF-
a may prove useful in clinical practice.
In summary, in this prospective study of acute phase
markers in pleural effusions in a strictly characterized
population, we report that pleural fluid CRP levels
45.3mg/dL may have diagnostic utility for the differentia-
tion of parapneumonic vs. tuberculous and malignant
effusions, IL-6 is increased in both tuberculous and
parapneumonic effusions and may be used to differentiate
them from malignancy, and TNF-a levels 488.1 pg/mL may
be useful for the differentiation between tuberculous and
malignant effusions. From a pathophysiologic point of view,
pleural fluid CRP levels seem to reflect the extent of
systemic inflammation, whereas IL-6 and TNF-a express the
local inflammatory response. These pilot data suggest that
these markers combined with clinical and routine laboratory
data may provide useful aids for the differentiation of
infectious and malignant pleural effusions in everyday
clinical practice.Acknowledgment
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